Healthcare Industry News: dermal patch
News Release - April 6, 2006
Dermisonics, Inc. Recruits Patients to Proceed With Human Pilot Trial-2 on U-Strip(TM) Ultrasonic Insulin Delivery System for Type-2 DiabeticsIRVINE, Calif., April 6 (HSMN NewsFeed) -- Dermisonics, Inc. (OTC Bulletin Board: DMSI.OB ), a medical device company focused on the development of painless, needle-free drug-delivery technology, has begun recruiting recipients to proceed with a planned Human Pilot Trial-2 on its U-Strip(TM) delivery system for use with insulin. This phase is being carried out on an initial group of Type-2 adult diabetics, which the Company believes represents the larger population of diabetics who could immediately benefit from this technology.
The U-Strip is a patented electronic system that uses a specialized form of ultrasound waves to enhance the delivery of drugs through the skin and into the bloodstream from a specially modified patch.
This clinical trial will test the Company's patented U-Strip ultrasonically assisted transdermal drug-delivery technology versus insulin pump technology. The goal is to deliver insulin via the U-Strip Insulin Patch up to one unit per hour, mirroring the exact delivery rate of a conventional insulin pump. This trial, to be conducted in Media, Pennsylvania under the direction of Rex Kessler, MD, will compare the invasive insulin pump to the delivery profile of the non-invasive U-Strip Insulin Patch over a five-hour test period.
Recruiting of volunteers began in April 2006 for the trials, which are slated to begin after the initial group of volunteer patients has completed the selection examination and enrollment process. The Company has already completed trial preparations including site selection, monitoring logistics and insurance bonding to cover trial participants. These preliminary steps clear the way for the trial to begin immediately following recruitment.
Inventor of Dermisonics' technology and Executive VP Bruce Redding states, "Dermisonics has chosen to start the clinical trial Human Pilot-2 with Type-2 diabetics because these recipients need a more regulated and consistent insulin dosing program than is available with ordinary medication. The data from this trial gives Dermisonics the data it needs to advance to a clinical trial on type-1 diabetics and children suffering Type-1 diabetes." Redding adds, "The U-Strip drug-delivery technology offers a totally non-invasive insulin delivery regimen -- no-needles, but also importantly -- a more uniform insulin dosing schedule than is currently available with either hypodermic needle injection, insulin pumps or type-2 medications."
About Dermisonics, Inc.
Dermisonics is an intellectual property company and technology incubator that is primarily focused on the ongoing development, testing and eventual commercialization of its active transdermal patch, called the U-Strip, that has been designed to facilitate the efficient and needle-free delivery of drugs with large molecular structures such as Insulin into the bloodstream. The Company has also developed other portable ultrasonic systems for applications in the medical (Antiseptic Wand) and skin care (U-Wand) fields.
For additional information see www.dermisonics.com
North American Investor Relations Contact:
International Market Trend
Toll-Free North America
European Investor Relations Contact:
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.